The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, ...
A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
FcRn blockade with nipocalimab necessitates pregnancy surveillance because placental FcRn drives maternal–fetal IgG transfer, ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to ...
Exploring the Link Between Football Players and ALS: Brian Lin, PhD In a recent Q&A interview, Brian Lin, PhD, research ...
In MuSK+ gMG, MG-ADL and QMG improvements with inebilizumab persisted to week 52, including after crossover from placebo during the open-label period. Protocol-driven corticosteroid tapering to ≤5 ...
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results